Begin vorige maand berichtten we over de TAILORx-studie, die liet zien dat adjuvante endocriene therapie en chemo-endocriene therapie vergelijkbare werkzaamheid hadden in vrouwen met HR-postief HER2-negatief kliernegatief mammacarcinoom met een midrange score op de 21-genentest. De aanleiding tot het bericht was de presentatie van prof. Joseph Sparano (Montefiore Medical Center, New York) op de ASCO Annual Meeting in Chicago. De studie is nu gepubliceerd in The New England Journal of Medicine, en voorzien van een nader-verhelderende video.

1.Sparano JA, Gray RJ, Makower D et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018;379:111-121


Summary: Last month we reported on the TAILORx-study, presented to the ASCO Annual Meeting by prof. Joseph Sparano. TAILORx showed that adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with HR-positive, HER2-negative, axillary node-negative breast cancer who had a midrange 21-gene recurrence score. Yesterday the study was published in The New England Journal of Medicine, illustrated by a video.